Katherine L Morel

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 8

Top Venues

Molecular cancer research : MCR

Cancer research communications

Nature cancer

Clinical & experimental metastasis

Dana Farber Cancer Institute

Flinders University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Dana Farber Cancer Institute

United States

Postdoctoral Fellow :: Oncologic Pathology

Flinders University

Australia

Research Assistant :: Flinders Centre for Innovation in Cancer

Flinders University

Australia

Research Assistant :: Haematology and Genetic Pathology

Flinders University

Australia

Technical Assistant :: Haematology and Genetic Pathology

Education History

Flinders University

Australia

PHD :: Flinders Centre for Innovation in Cancer

Flinders University

Australia

BSC

Flinders University

Australia

BSC

Publications

Beatriz German, Sarah Abou Alaiwi, Kun-Lin Ho, Jagpreet S Nanda, Marcos A S Fonseca, Deborah L Burkhart, Anjali V Sheahan, Hannah E Bergom, Katherine L Morel, Himisha Beltran, Justin H Hwang, Matthew L Freedman, Kate Lawrenson, Leigh Ellis
MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer. Cancer research communications 4 (9) (2024)
Beatriz German, Jagpreet N Singh, Marcos AdS Fonseca, Deborah L Burkhart, Anjali Sheahan, Hannah Bergom, Katherine L Morel, Himisha Beltran, Justin H Hwang, Kate Lawrenson, Leigh Ellis
MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer. bioRxiv : the preprint server for biology (2024)
Beatriz German, Sarah Abou Alaiwi, Kun-Lin Ho, Jagpreet S Nanda, Marcos A S Fonseca, Deborah L Burkhart, Anjali V Sheahan, Hannah E Bergom, Katherine L Morel, Himisha Beltran, Justin H Hwang, Matthew L Freedman, Kate Lawrenson, Leigh Ellis
MYBL2 Drives Prostate Cancer Plasticity: Inhibiting its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer. Cancer research communications (2024)
Katherine L Morel, Anjali V Sheahan, Deborah L Burkhart, Sylvan C Baca, Nadia Boufaied, Yin Liu, Xintao Qiu, Israel Cañadas, Kevin Roehle, Max Heckler, Carla Calagua, Huihui Ye, Constantia Pantelidou, Phillip M Galbo, Sukanya Panja, Antonina Mitrofanova, Scott Wilkinson, Nichelle C Whitlock, Shana Y Trostel, Anis A Hamid, Adam S Kibel, David A Barbie, Atish D Choudhury, Mark M Pomerantz, Christopher J Sweeney, Henry W Long, David J Einstein, Geoffrey I Shapiro, Stephanie K Dougan, Adam G Sowalsky, Housheng Hansen He, Matthew L Freedman, Steven P Balk, Massimo Loda, David P Labbé, Brian M Olson, Leigh Ellis
EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nature cancer 2 (4) (2021)
Katherine L Morel, Anis A Hamid, John Gerard Clohessy, Nicole Pandell, Leigh Ellis, Christopher J Sweeney
NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. Molecular cancer research : MCR 19 (7) (2021)
Halena R VanDeusen, Johnny R Ramroop, Katherine L Morel, Song Yi Bae, Anjali V Sheahan, Zoi Sychev, Nathan A Lau, Larry C Cheng, Victor M Tan, Zhen Li, Ashley Petersen, John K Lee, Jung Wook Park, Rendong Yang, Justin H Hwang, Ilsa Coleman, Owen N Witte, Colm Morrissey, Eva Corey, Peter S Nelson, Leigh Ellis, Justin M Drake
Targeting RET Kinase in Neuroendocrine Prostate Cancer. Molecular cancer research : MCR 18 (8) (2020)
Deborah L Burkhart, Katherine L Morel, Kristine M Wadosky, David P Labbé, Phillip M Galbo, Zafardjan Dalimov, Bo Xu, Massimo Loda, Leigh Ellis
Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer. Cancer prevention research (Philadelphia, Pa.) 13 (12) (2020)
Katherine L Morel, Rebecca J Ormsby, Emma L Solly, Linh N K Tran, Christopher J Sweeney, Sonja Klebe, Nils Cordes, Pamela J Sykes
Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide. Clinical & experimental metastasis 35 (7) (2018)

Katherine L Morel.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Katherine L Morel